Cargando…

Human monoclonal antibodies inhibit invasion of transgenic Plasmodium knowlesi expressing Plasmodium vivax Duffy binding protein

BACKGROUND: Plasmodium vivax has been more resistant to various control measures than Plasmodium falciparum malaria because of its greater transmissibility and ability to produce latent parasite forms. Therefore, developing P. vivax vaccines and therapeutic monoclonal antibodies (humAbs) remains a h...

Descripción completa

Detalles Bibliográficos
Autores principales: Watson, Quentin D., Carias, Lenore L., Malachin, Alyssa, Redinger, Karli R., Bosch, Jürgen, Bardelli, Martino, Baldor, Lea, Feufack-Donfack, Lionel Brice, Popovici, Jean, Moon, Robert W., Draper, Simon J., Zimmerman, Peter A., King, Christopher L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696754/
https://www.ncbi.nlm.nih.gov/pubmed/38049801
http://dx.doi.org/10.1186/s12936-023-04766-1
_version_ 1785154635868143616
author Watson, Quentin D.
Carias, Lenore L.
Malachin, Alyssa
Redinger, Karli R.
Bosch, Jürgen
Bardelli, Martino
Baldor, Lea
Feufack-Donfack, Lionel Brice
Popovici, Jean
Moon, Robert W.
Draper, Simon J.
Zimmerman, Peter A.
King, Christopher L.
author_facet Watson, Quentin D.
Carias, Lenore L.
Malachin, Alyssa
Redinger, Karli R.
Bosch, Jürgen
Bardelli, Martino
Baldor, Lea
Feufack-Donfack, Lionel Brice
Popovici, Jean
Moon, Robert W.
Draper, Simon J.
Zimmerman, Peter A.
King, Christopher L.
author_sort Watson, Quentin D.
collection PubMed
description BACKGROUND: Plasmodium vivax has been more resistant to various control measures than Plasmodium falciparum malaria because of its greater transmissibility and ability to produce latent parasite forms. Therefore, developing P. vivax vaccines and therapeutic monoclonal antibodies (humAbs) remains a high priority. The Duffy antigen receptor for chemokines (DARC) expressed on erythrocytes is central to P. vivax invasion of reticulocytes. P. vivax expresses a Duffy binding protein (PvDBP) on merozoites, a DARC ligand, and the DARC: PvDBP interaction is critical for P. vivax blood stage malaria. Therefore, PvDBP is a leading vaccine candidate for P. vivax and a target for therapeutic human monoclonal antibodies (humAbs). METHODS: Here, the functional activity of humAbs derived from naturally exposed and vaccinated individuals are compared for the first time using easily cultured Plasmodium knowlesi (P. knowlesi) that had been genetically modified to replace its endogenous PkDBP orthologue with PvDBP to create a transgenic parasite, PkPvDBPOR. This transgenic parasite requires DARC to invade human erythrocytes but is not reticulocyte restricted. This model was used to evaluate the invasion inhibition potential of 12 humAbs (9 naturally acquired; 3 vaccine-induced) targeting PvDBP individually and in combinations using growth inhibition assays (GIAs). RESULTS: The PvDBP-specific humAbs demonstrated 70–100% inhibition of PkPvDBPOR invasion with the IC(50) values ranging from 51 to 338 µg/mL for the 9 naturally acquired (NA) humAbs and 33 to 99 µg/ml for the 3 vaccine-induced (VI) humAbs. To evaluate antagonistic, additive, or synergistic effects, six pairwise combinations were performed using select humAbs. Of these combinations tested, one NA/NA (099100/094083) combination demonstrated relatively strong additive inhibition between 10 and 100 µg/mL; all combinations of NA and VI humAbs showed additive inhibition at concentrations below 25 µg/mL and antagonism at higher concentrations. None of the humAb combinations showed synergy. Invasion inhibition efficacy by some mAbs shown with PkPvDBPOR was closely replicated using P. vivax clinical isolates. CONCLUSION: The PkPvDBPOR transgenic model is a robust surrogate of P. vivax to assess invasion and growth inhibition of human monoclonal Abs recognizing PvDBP individually and in combination. There was no synergistic interaction for growth inhibition with the humAbs tested here that target different epitopes or subdomains of PvDBP, suggesting little benefit in clinical trials using combinations of these humAbs.
format Online
Article
Text
id pubmed-10696754
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106967542023-12-06 Human monoclonal antibodies inhibit invasion of transgenic Plasmodium knowlesi expressing Plasmodium vivax Duffy binding protein Watson, Quentin D. Carias, Lenore L. Malachin, Alyssa Redinger, Karli R. Bosch, Jürgen Bardelli, Martino Baldor, Lea Feufack-Donfack, Lionel Brice Popovici, Jean Moon, Robert W. Draper, Simon J. Zimmerman, Peter A. King, Christopher L. Malar J Research BACKGROUND: Plasmodium vivax has been more resistant to various control measures than Plasmodium falciparum malaria because of its greater transmissibility and ability to produce latent parasite forms. Therefore, developing P. vivax vaccines and therapeutic monoclonal antibodies (humAbs) remains a high priority. The Duffy antigen receptor for chemokines (DARC) expressed on erythrocytes is central to P. vivax invasion of reticulocytes. P. vivax expresses a Duffy binding protein (PvDBP) on merozoites, a DARC ligand, and the DARC: PvDBP interaction is critical for P. vivax blood stage malaria. Therefore, PvDBP is a leading vaccine candidate for P. vivax and a target for therapeutic human monoclonal antibodies (humAbs). METHODS: Here, the functional activity of humAbs derived from naturally exposed and vaccinated individuals are compared for the first time using easily cultured Plasmodium knowlesi (P. knowlesi) that had been genetically modified to replace its endogenous PkDBP orthologue with PvDBP to create a transgenic parasite, PkPvDBPOR. This transgenic parasite requires DARC to invade human erythrocytes but is not reticulocyte restricted. This model was used to evaluate the invasion inhibition potential of 12 humAbs (9 naturally acquired; 3 vaccine-induced) targeting PvDBP individually and in combinations using growth inhibition assays (GIAs). RESULTS: The PvDBP-specific humAbs demonstrated 70–100% inhibition of PkPvDBPOR invasion with the IC(50) values ranging from 51 to 338 µg/mL for the 9 naturally acquired (NA) humAbs and 33 to 99 µg/ml for the 3 vaccine-induced (VI) humAbs. To evaluate antagonistic, additive, or synergistic effects, six pairwise combinations were performed using select humAbs. Of these combinations tested, one NA/NA (099100/094083) combination demonstrated relatively strong additive inhibition between 10 and 100 µg/mL; all combinations of NA and VI humAbs showed additive inhibition at concentrations below 25 µg/mL and antagonism at higher concentrations. None of the humAb combinations showed synergy. Invasion inhibition efficacy by some mAbs shown with PkPvDBPOR was closely replicated using P. vivax clinical isolates. CONCLUSION: The PkPvDBPOR transgenic model is a robust surrogate of P. vivax to assess invasion and growth inhibition of human monoclonal Abs recognizing PvDBP individually and in combination. There was no synergistic interaction for growth inhibition with the humAbs tested here that target different epitopes or subdomains of PvDBP, suggesting little benefit in clinical trials using combinations of these humAbs. BioMed Central 2023-12-04 /pmc/articles/PMC10696754/ /pubmed/38049801 http://dx.doi.org/10.1186/s12936-023-04766-1 Text en © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Watson, Quentin D.
Carias, Lenore L.
Malachin, Alyssa
Redinger, Karli R.
Bosch, Jürgen
Bardelli, Martino
Baldor, Lea
Feufack-Donfack, Lionel Brice
Popovici, Jean
Moon, Robert W.
Draper, Simon J.
Zimmerman, Peter A.
King, Christopher L.
Human monoclonal antibodies inhibit invasion of transgenic Plasmodium knowlesi expressing Plasmodium vivax Duffy binding protein
title Human monoclonal antibodies inhibit invasion of transgenic Plasmodium knowlesi expressing Plasmodium vivax Duffy binding protein
title_full Human monoclonal antibodies inhibit invasion of transgenic Plasmodium knowlesi expressing Plasmodium vivax Duffy binding protein
title_fullStr Human monoclonal antibodies inhibit invasion of transgenic Plasmodium knowlesi expressing Plasmodium vivax Duffy binding protein
title_full_unstemmed Human monoclonal antibodies inhibit invasion of transgenic Plasmodium knowlesi expressing Plasmodium vivax Duffy binding protein
title_short Human monoclonal antibodies inhibit invasion of transgenic Plasmodium knowlesi expressing Plasmodium vivax Duffy binding protein
title_sort human monoclonal antibodies inhibit invasion of transgenic plasmodium knowlesi expressing plasmodium vivax duffy binding protein
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696754/
https://www.ncbi.nlm.nih.gov/pubmed/38049801
http://dx.doi.org/10.1186/s12936-023-04766-1
work_keys_str_mv AT watsonquentind humanmonoclonalantibodiesinhibitinvasionoftransgenicplasmodiumknowlesiexpressingplasmodiumvivaxduffybindingprotein
AT cariaslenorel humanmonoclonalantibodiesinhibitinvasionoftransgenicplasmodiumknowlesiexpressingplasmodiumvivaxduffybindingprotein
AT malachinalyssa humanmonoclonalantibodiesinhibitinvasionoftransgenicplasmodiumknowlesiexpressingplasmodiumvivaxduffybindingprotein
AT redingerkarlir humanmonoclonalantibodiesinhibitinvasionoftransgenicplasmodiumknowlesiexpressingplasmodiumvivaxduffybindingprotein
AT boschjurgen humanmonoclonalantibodiesinhibitinvasionoftransgenicplasmodiumknowlesiexpressingplasmodiumvivaxduffybindingprotein
AT bardellimartino humanmonoclonalantibodiesinhibitinvasionoftransgenicplasmodiumknowlesiexpressingplasmodiumvivaxduffybindingprotein
AT baldorlea humanmonoclonalantibodiesinhibitinvasionoftransgenicplasmodiumknowlesiexpressingplasmodiumvivaxduffybindingprotein
AT feufackdonfacklionelbrice humanmonoclonalantibodiesinhibitinvasionoftransgenicplasmodiumknowlesiexpressingplasmodiumvivaxduffybindingprotein
AT popovicijean humanmonoclonalantibodiesinhibitinvasionoftransgenicplasmodiumknowlesiexpressingplasmodiumvivaxduffybindingprotein
AT moonrobertw humanmonoclonalantibodiesinhibitinvasionoftransgenicplasmodiumknowlesiexpressingplasmodiumvivaxduffybindingprotein
AT drapersimonj humanmonoclonalantibodiesinhibitinvasionoftransgenicplasmodiumknowlesiexpressingplasmodiumvivaxduffybindingprotein
AT zimmermanpetera humanmonoclonalantibodiesinhibitinvasionoftransgenicplasmodiumknowlesiexpressingplasmodiumvivaxduffybindingprotein
AT kingchristopherl humanmonoclonalantibodiesinhibitinvasionoftransgenicplasmodiumknowlesiexpressingplasmodiumvivaxduffybindingprotein